Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 12/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877385 | 0.75 | HRH4 (0.62) | TYMSHRH4NPY5REPHA4 | |
| SCHEMBL6654515 | 0.74 | TYMS (1.00) | TYMS | |
| SCHEMBL9166765 | 0.72 | TYMS (0.61) | TYMSHRH4XDH | |
| SCHEMBL4878269 | 0.72 | HRH4 (0.55) | TYMSHRH4NPY5REPHA4 | |
| SCHEMBL606792 | 0.69 | HRH4 (1.00) | HRH4NPY5R | |
| SCHEMBL29416781 | 0.68 | XDH (0.52) | TYMSXDH | |
| SCHEMBL1593704 | 0.68 | FBP1 (0.63) | NPY5R | |
| SCHEMBL29446042 | 0.67 | MAOA (0.53) | TYMSNPY5RPARP1PARP10 | |
| SCHEMBL769238 | 0.67 | MAOA (0.53) | TYMSNPY5RPARP1PARP10 | |
| SCHEMBL12177490 | 0.67 | NPY5R (0.49) | TYMSHRH4NPY5RPARP1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | INSIGNIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| CN-117177963-A | Microbiocidal quinoline/quinoxaline isoquinoline derivatives | 先正达农作物保护股份公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| CN-111565716-B | Method of using dipivefrin | 因斯格尼斯疗法有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | INSIGNIS THERAPEUTICS INC (US) | 2022-06-23 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | TYMS 3574/4885HRH4 44/4885NPY5R 94/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | TYMS 2631/4885HRH4 2243/4885NPY5R 2362/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | TYMS 2241/4885HRH4 3066/4885NPY5R 1950/4885 |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | TYMS 3574/4885HRH4 44/4885NPY5R 94/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | TYMS 2631/4885HRH4 2243/4885NPY5R 2362/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | TYMS 2241/4885HRH4 3066/4885NPY5R 1950/4885 |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | ADRB3, ADRB2, ADRB1 | TYMS 4228/4885HRH4 102/4885NPY5R 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.